Modulation of drug-induced hematopoietic toxicity with zinc in murine bone marrow cells (BMC) (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Modulation of drug-induced hematopoietic toxicity with zinc in murine bone marrow cells (BMC) (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 34:A1700 1993. Unique Identifier : AIDSLINE ICDB/93692641
Gogu SR; Agrawal KC; Dept. of Pharmacology, Tulane Univ. Sch. of Medicine, New; Orleans, LA 70112

Abstract: Drug-induced hematopoietic toxicity is a major limiting factor in the administration of anticancer and anti-HIV drugs. Zinc supplementation has been shown to stimulate immunological function and its deficiency to cause atrophy of the thymus and spleen. We have investigated the role of zinc in reversing zidovudine (AZT)-induced bone marrow toxicity. Murine BMC (1 x 10(6) cells) were exposed to various concentrations (1-20 uM) of AZT in the presence and absence of zinc acetate (100 uM). The cell survival was determined by the colony-forming assays of erythroid (CFU-E) and granulocytic (CFU-GM) lineage. The IC50 values in the presence of zinc were increased approx 3-fold (from 2.4 to 6.6 uM) for CFU-E and 2-fold (for 3.9 to 8.7 uM) for CFU-GM. To delineate the mechanism of this significant protection of BMC, we have monitored the mRNA levels of metallothionein (MT) by using a 31-mer cDNA probe. Zinc produces a concentration-dependent increase in the MT mRNA levels. These results suggest that zinc supplementation can be conveniently used to reduce AZT-induced erythroid toxicity.
Keywords: Animal Bone Marrow Diseases/CHEMICALLY INDUCED/*THERAPY Hematopoietic Stem Cells/*CYTOLOGY Metallothionein/GENETICS Mice RNA, Messenger/METABOLISM Zidovudine/*ADVERSE EFFECTS Zinc/*THERAPEUTIC USE ABSTRACTKWDanimalbonemarrowdiseases/chemicallyinduced/KWDtherapyhematopoieticstemcells/KWDcytologymetallothionein/geneticsmicerna,messenger/metabolismzidovudine/KWDadverseeffectszinc/KWDtherapeuticuseabstract
930730
M9370995

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .